AVRO AVROBIO, Inc. Stock Quote

AVRO [NASD]

Index	-	P/E	-	EPS (ttm)	-2.86	Insider Own	2.59%	Shs Outstand	43.62M	Perf Week	-6.45%
Market Cap	77.20M	Forward P/E	-	EPS next Y	-2.18	Insider Trans	0.00%	Shs Float	42.54M	Perf Month	-52.46%
Income	-119.00M	PEG	-	EPS next Q	-0.74	Inst Own	86.50%	Short Float	3.82%	Perf Quarter	-67.60%
Sales	-	P/S	-	EPS this Y	-24.30%	Inst Trans	0.08%	Short Ratio	2.36	Perf Half Y	-76.26%
Book/sh	4.44	P/B	0.39	EPS next Y	13.90%	ROA	-49.00%	Target Price	7.00	Perf Year	-87.83%
Cash/sh	4.54	P/C	0.38	EPS next 5Y	-	ROE	-52.80%	52W Range	1.67 - 20.07	Perf YTD	-54.81%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-91.33%	Beta	1.64
Dividend %	-	Quick Ratio	9.30	Sales past 5Y	-	Gross Margin	-	52W Low	3.88%	ATR	0.22
Employees	121	Current Ratio	9.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	22.14	Volatility	9.54% 9.30%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	25.90%	Profit Margin	-	Rel Volume	0.66	Prev Close	1.84
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 BMO	Payout	-	Avg Volume	686.73K	Price	1.74
Recom	2.20	SMA20	-27.88%	SMA50	-48.59%	SMA200	-73.44%	Volume	452,242	Change	-5.43%

Jan-05-22

Downgrade

BTIG Research

Buy → Neutral

Nov-19-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$24 → $7

Jun-15-21

Initiated

BTIG Research

Buy

$23

May-27-21

Initiated

Needham

Buy

$28

Mar-09-21

Initiated

Barclays

Overweight

$23

Mar-02-21

Initiated

Stifel

Hold

$14

Nov-11-20

Initiated

Berenberg

Buy

Mar-31-20

Downgrade

H.C. Wainwright

Buy → Neutral

$13

Jun-27-19

Initiated

Mizuho

Buy

$28

Apr-05-19

Initiated

Janney

Buy

Oct-10-18

Initiated

Guggenheim

Buy

Oct-02-18

Reiterated

H.C. Wainwright

Buy

$47 → $40

Sep-17-18

Initiated

H.C. Wainwright

Buy

$47

Jul-16-18

Initiated

Wells Fargo

Outperform

$40

Jul-16-18

Initiated

Wedbush

Outperform

$38

Jul-16-18

Initiated

Morgan Stanley

Overweight

$37

Jan-27-22 07:00AM	AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium 2022 Business Wire -5.43%
Jan-25-22 10:00AM	Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now Zacks
Jan-07-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks Zacks
Jan-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-04-22 02:28PM	AvroBio shares plunge after company halts development of Fabry drug American City Business Journals -36.63%
09:07AM	Wedbush Says Avrobio Shares Still Undervalued Despite 33% Fall Investing.com
07:57AM	Why Avrobio's Shares Are Plunging Today Benzinga
07:00AM	AVROBIO Reprioritizes Pipeline Programs Business Wire
Dec-07-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +7.67%
Dec-04-21 06:25AM	Is AVROBIO (NASDAQ:AVRO) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Nov-24-21 07:00AM	AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1 Business Wire
Nov-09-21 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in November Business Wire
Nov-08-21 07:00AM	AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference Business Wire
Nov-05-21 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-04-21 07:00AM	AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update Business Wire
Nov-03-21 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome Business Wire +7.46%
Oct-26-21 07:00AM	AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer Business Wire
Oct-20-21 07:00AM	AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit Business Wire
Oct-19-21 07:00AM	AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1 Business Wire
Oct-06-21 07:00AM	AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress Business Wire +5.06%
Oct-05-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-05-21 08:25AM	What Is The Ownership Structure Like For AVROBIO, Inc. (NASDAQ:AVRO)? Simply Wall St.
Sep-03-21 04:01PM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -7.66%
Sep-01-21 07:00AM	AVROBIO to Participate at Four Upcoming Investor Conferences Business Wire
Aug-05-21 07:00AM	AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire +7.59%
Aug-04-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-02-21 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in August Business Wire
Jul-12-21 08:49AM	10 Best Stocks Under $10 to Buy Right Now Insider Monkey -6.41%
Jul-08-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-27-21 01:39PM	3 Strong Buy Stocks Under $10 That Can Rip Higher TipRanks
Jun-17-21 09:43AM	Gene Therapy Companies Undervalued, Positioned for Upside TipRanks
Jun-10-21 07:00AM	AVROBIO to Present at the JMP Securities Life Sciences Conference Business Wire
Jun-07-21 01:37PM	How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks Barrons.com +7.00%
Jun-04-21 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-13-21 07:00AM	AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update Business Wire
May-12-21 08:32AM	Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season? Zacks
May-06-21 01:49PM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm PR Newswire
07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-05-21 10:24AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
May-04-21 03:40PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire -5.27%
02:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of AVROBIO, Inc. (AVRO) Investigation ACCESSWIRE
11:06AM	BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation AVRO Business Wire
01:56AM	We're Hopeful That AVROBIO (NASDAQ:AVRO) Will Use Its Cash Wisely Simply Wall St.
May-03-21 09:42AM	Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy Benzinga -18.84%
07:00AM	AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease Business Wire
Apr-27-21 04:30PM	AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting Business Wire
Apr-20-21 12:00PM	AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Apr-06-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -7.22%
Mar-18-21 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update Business Wire -6.64%
Mar-05-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +7.40%
Mar-01-21 07:00AM	AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD04, an Investigational Gene Therapy for Cystinosis Business Wire
Feb-25-21 07:00AM	AVROBIO to Present at Three Upcoming Investor Conferences in March Business Wire
Feb-08-21 08:07AM	Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study Benzinga +12.80%
07:00AM	AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial Business Wire
Feb-05-21 04:05PM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.77%
Feb-01-21 07:00AM	AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium 2021 Business Wire
Jan-22-21 07:00AM	AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit Business Wire
Jan-19-21 07:00AM	AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer Business Wire
Jan-08-21 07:00AM	AVROBIO to Present at the ICR Conference 2021 Business Wire
Jan-07-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.14%
Dec-16-20 10:46AM	Is AVRO A Good Stock To Buy Now? Insider Monkey +5.00%
Dec-04-20 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-24-20 04:19PM	AVROBIO Announces Closing of Underwritten Public Offering Business Wire
Nov-19-20 10:06PM	AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock Business Wire
04:09PM	AVROBIO Announces Proposed Public Offering of Common Stock Business Wire
Nov-17-20 07:00AM	AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline Business Wire
Nov-06-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-05-20 07:00AM	AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire -10.50%
06:18AM	Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation Simply Wall St.
Oct-29-20 07:00AM	AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD01, an Investigational Gene Therapy for Fabry Disease Business Wire
Oct-26-20 07:00AM	AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day Business Wire
Oct-21-20 07:00AM	AVROBIO Appoints Dr. Gail Farfel to its Board of Directors Business Wire
Oct-06-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-05-20 07:00AM	AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome Business Wire +10.79%
Sep-29-20 10:48AM	AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status Zacks
Sep-28-20 07:00AM	AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease Business Wire
Sep-25-20 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences Business Wire
Sep-04-20 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-03-20 07:00AM	AVROBIO to Present at Three Upcoming Investor Conferences Business Wire
Aug-12-20 09:41AM	Did Hedge Funds Make The Right Call On AVROBIO, Inc. (AVRO) ? Insider Monkey
Aug-07-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-06-20 07:00AM	AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire
Aug-05-20 07:00AM	AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
Jul-27-20 08:23AM	AVROBIO Sees Hammer Chart Pattern: Time to Buy? Zacks +6.18%
Jul-08-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-06-20 07:00AM	AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials Business Wire
Jun-29-20 07:00AM	AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer Business Wire -5.03%
Jun-24-20 04:16PM	Here is What Hedge Funds Think About AVROBIO, Inc. (AVRO) Insider Monkey -7.71%
May-14-20 07:00AM	AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020 Business Wire -6.99%
May-13-20 07:00AM	AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis Business Wire
May-09-20 08:36AM	We're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Rate Simply Wall St.
May-08-20 08:42AM	Why Earnings Season Could Be Great for AVROBIO (AVRO) Zacks
May-07-20 07:00AM	AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update Business Wire
May-06-20 04:05PM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:00AM	AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies Business Wire
May-05-20 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020 Business Wire +15.01%
May-04-20 07:00AM	AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIOs Proprietary Platform Globally Business Wire
Apr-14-20 08:58AM	Is AVROBIO (AVRO) Stock a Solid Choice Right Now? Zacks +7.47%
Apr-12-20 02:26PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO PR Newswire
02:26PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO CNW Group

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vickers Philip J.	Director	Jul 07	Buy	8.35	4,800	40,080	4,800	Jul 08 04:21 PM
Donenberg Phillip B.	Director	Feb 17	Buy	11.71	2,000	23,420	2,000	Feb 18 07:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience